"Thanks to a breakthrough in RNA manipulation, crop scientists have developed new potato and rice varieties with higher yields and increased drought tolerance," reports UPI: By inserting a gene responsible for production of a protein called FTO, scientists produced bigger rice and potato plants with more expansive root systems. In experiments, the plants' longer roots improved their drought resistance. Test results — detailed Thursday in the journal Nature Biotechnology — showed the RNA-manipulated plants also improved their rate of photosynthesis, boost yields by as much as 50 percent... In the lab, the manipulated rice plants grew at three times their normal rate. In the field, the rice plants increased their mass by 50 percent. They also sprouted longer roots, increased their photosynthesis rate and produced larger yields. When they repeated the experiments with potato plants, the researchers got similar results, suggesting the new gene manipulation method could be used to bolster a variety of crops. The researchers hope this could help crops survive climate change, and even prevent forests from being cleared for food production, according to the article. And one of the study's co-authors adds "This really provides the possibility of engineering plants to potentially improve the ecosystem as global warming proceeds."

Read more of this story at Slashdot.

USA Today reports: Companies like Moderna and Pfizer's partner BioNTech, whose names are familiar from COVID-19 vaccines, are using mRNA to spur cancer patients' bodies to make vaccines that will — hopefully — prevent recurrences and treatments designed to fight off advanced tumors. If they prove effective, which won't be known for at least another year or two, they could be added to the arsenal of immune therapies designed to get the body to fight off its own tumors... Over the last decade, pharmaceutical companies around the world have been developing new ways to train the body's immune system to fight off tumors, particularly melanoma. They had learned how to remove a brake installed by tumors, unleashing the warriors of the immune system. Ten years ago, only about 5% of people with advanced melanoma survived for five years. Now, nearly half make it that long. Trials of mRNA cancer vaccines aim to boost that number even higher by adding soldiers to the fight... Once a tumor has been largely removed through surgery, a vaccine can help generate new immune soldiers known as T cells... A computer algorithm analyzes the mutations distinct to the cancer cells, looking for ones that trigger the production of T cells, said Melissa J. Moore, Moderna's chief scientific officer, of platform research. So far, she said, Moderna, working with partner Merck, has tested these personalized vaccines in about 100 patients. They aim eventually to make a personalized mRNA vaccine within about 45 days after the patient's cancer surgery, during their recovery... Mutated cancer cells have proteins on their surface that can be targeted by an mRNA vaccine. For a tumor that has, say, five common mutations, a patient could get a combination of five of these vaccines. On Friday, BioNTech announced it was launching a new trial for this approach, testing it in 120 melanoma patients Europe, the United Kingdom, Australia and the U.S. The new treatment, given in connection with an antibody from Regeneron, is aimed at four tumor-associated antigens. More than 90% of melanoma tumors contain at least one of the four. The U.S. federal government now lists 29 studies underway or that will be soon investigating mRNA cancer vaccines, according to the article. And Dr. Stephen Hahn, who had a career as an oncologist before running the Food and Drug Administration from 2019 until early this year, "said he's more optimistic this time because of how much researchers have learned about the role the immune system plays in cancer. 'That gives us an edge to maybe finally get to the place where we need to be.'"

Read more of this story at Slashdot.

Implantable miniaturized medical devices that wirelessly transmit data "are transforming healthcare and improving the quality of life for millions of people," writes Columbia University, noting the devices are "widely used to monitor and map biological signals, to support and enhance physiological functions, and to treat diseases." Long-time Slashdot reader sandbagger shares the university's newest announcement: These devices could be used to monitor physiological conditions, such as temperature, blood pressure, glucose, and respiration for both diagnostic and therapeutic procedures. To date, conventional implanted electronics have been highly volume-inefficient — they generally require multiple chips, packaging, wires, and external transducers, and batteries are often needed for energy storage... Researchers at Columbia Engineering report that they have built what they say is the world's smallest single-chip system, consuming a total volume of less than 0.1 mm cubed. The system is as small as a dust mite and visible only under a microscope... "We wanted to see how far we could push the limits on how small a functioning chip we could make," said the study's leader Ken Shepard, Lau Family professor of electrical engineering and professor of biomedical engineering. "This is a new idea of 'chip as system' — this is a chip that alone, with nothing else, is a complete functioning electronic system. This should be revolutionary for developing wireless, miniaturized implantable medical devices that can sense different things, be used in clinical applications, and eventually approved for human use...." The chip, which is the entire implantable/injectable mote with no additional packaging, was fabricated at the Taiwan Semiconductor Manufacturing Company with additional process modifications performed in the Columbia Nano Initiative cleanroom and the City University of New York Advanced Science Research Center (ASRC) Nanofabrication Facility. Shepard commented, "This is a nice example of 'more than Moore' technology—we introduced new materials onto standard complementary metal-oxide-semiconductor to provide new function. In this case, we added piezoelectric materials directly onto the integrated circuit to transducer acoustic energy to electrical energy...." The team's goal is to develop chips that can be injected into the body with a hypodermic needle and then communicate back out of the body using ultrasound, providing information about something they measure locally. The current devices measure body temperature, but there are many more possibilities the team is working on.

Read more of this story at Slashdot.

CNN recently reported on "a batch" of new studies published Wednesday — with one quantifying how much immunity improves after the second dose, and others showing how well coronavirus vaccines work against new variants of the virus: The first nationwide study of coronavirus vaccination, done in Israel, showed Pfizer/BioNtech's vaccine works far better after two doses. Two shots of the vaccine provided greater than 95% protection from infection, severe illness and death, Dr. Eric Haas of the Israel Ministry of Health and colleagues reported in the Lancet medical journal. "Two doses of BNT162b2 are highly effective across all age groups in preventing symptomatic and asymptomatic SARS-CoV-2 infections and COVID-19-related hospitalizations, severe disease, and death, including those caused by the B.1.1.7 SARS-CoV-2 variant," they wrote. The B.1.1.7 variant, first seen in Britain, has spread widely and is now the most common new variant seen in the US. It was also common in Israel when the study was done... "By 14 days after vaccination, protections conferred by a second dose [of the Pfizer vaccine] increased to 96.5% protection against infection, 98% against hospitalization, and 98.1% against death," the team wrote. But people who got only one dose of the vaccine were far less protected. One dose alone gave just 57.7% protection against infection, 75.7% against hospitalization, and 77% against death.... Separately, a team in the Gulf state of Qatar looked at the efficacy of Pfizer's vaccine in the population there when B.1.351 and B.1.1.7 were both circulating. They found reassuring results. "The estimated effectiveness of the vaccine against any documented infection with the B.1.1.7 variant was 89.5% at 14 or more days after the second dose. The effectiveness against any documented infection with the B.1.351 variant was 75%," the researchers wrote in a letter to the New England Journal of Medicine... Vaccine maker Moderna reported Wednesday that a booster shot delivering a half-dose of its current vaccine revs up the immune response against both B.1.351 and P.1. And a booster dose formulated specifically to match B.1.351 was even more effective, Moderna said in a statement... In another study, vaccine maker Novavax confirmed earlier findings that showed its vaccine protects against B.1.351.

Read more of this story at Slashdot.

An anonymous reader quotes a report from the BBC: The world's biggest jeweller, Pandora, says it will no longer sell mined diamonds and will switch to exclusively laboratory-made diamonds. Concerns about the environment and working practices in the mining industry have led to growing demand for alternatives to mined diamonds. Pandora's chief executive, Alexander Lacik, told the BBC the change was part of a broader sustainability drive. He said the firm was pursuing it because "it's the right thing to do." They are also cheaper: "We can essentially create the same outcome as nature has created, but at a very, very different price." Mr Lacik explains they can be made for as little as "a third of what it is for something that we've dug up from the ground." Pandora's lab-made diamonds are being made in Britain, and the UK is the first country where they will be sold. The new diamond jewelry will start at $350. [...] One problem with lab-made diamonds, though, is that they can take a lot of energy to produce. Between 50% and 60% of them come from China, where they are made in a process known as "high-pressure, high-temperature technology." The use of coal powered electricity is widespread. However in the United States, the biggest retail market for lab-grown diamonds, there is a greater focus on using renewable energy. The largest US producer, Diamond Foundry, says its process is "100% hydro-powered, meaning zero emissions." Both types are chemically and physically identical to mined diamonds.

Read more of this story at Slashdot.

Long-time Slashdot reader destinyland writes: The New York Times tells the story of Hungarian-born Dr. Kariko, whose father was a butcher and who growing up had never met a scientist — but knew they wanted to be one. Despite earning a Ph.D. at Hungary's University of Szeged and working as a postdoctoral fellow at its Biological Research Center, Kariko never found a permanent position after moving to the U.S., "instead clinging to the fringes of academia." Now 66 years old, Dr. Kariko is suddenly being hailed as "one of the heroes of Covid-19 vaccine development," after spending an entire career focused on mRNA, "convinced mRNA could be used to instruct cells to make their own medicines, including vaccines." From the article: For many years her career at the University of Pennsylvania was fragile. She migrated from lab to lab, relying on one senior scientist after another to take her in. She never made more than $60,000 a year... She needed grants to pursue ideas that seemed wild and fanciful. She did not get them, even as more mundane research was rewarded. "When your idea is against the conventional wisdom that makes sense to the star chamber, it is very hard to break out," said Dr. David Langer, a neurosurgeon who has worked with Dr. Kariko... Kariko's husband, Bela Francia, manager of an apartment complex, once calculated that her endless workdays meant she was earning about a dollar an hour. The Times also describes a formative experience in 1989 with cardiologist Elliot Barnathan: One fateful day, the two scientists hovered over a dot-matrix printer in a narrow room at the end of a long hall. A gamma counter, needed to track the radioactive molecule, was attached to a printer. It began to spew data. Their detector had found new proteins produced by cells that were never supposed to make them — suggesting that mRNA could be used to direct any cell to make any protein, at will. "I felt like a god," Dr. Kariko recalled. Yet Kariko was eventually left without a lab or funds for research, until a chance meeting at a photocopying machine led to a partnership with Dr. Drew Weissman of the University of Pennsylvania: "We both started writing grants," Dr. Weissman said. "We didn't get most of them. People were not interested in mRNA. The people who reviewed the grants said mRNA will not be a good therapeutic, so don't bother.'" Leading scientific journals rejected their work. When the research finally was published, in Immunity, it got little attention... "We talked to pharmaceutical companies and venture capitalists. No one cared," Dr. Weissman said. "We were screaming a lot, but no one would listen." Eventually, though, two biotech companies took notice of the work: Moderna, in the United States, and BioNTech, in Germany. Pfizer partnered with BioNTech, and the two now help fund Dr. Weissman's lab.

Read more of this story at Slashdot.

"Scientists have demonstrated the first human use of a wireless brain-computer interface, a potential breakthrough for people with paralysis," reports The Next Web (in a story shared by Slashdot reader Hmmmmmm): While traditional BCIs are tethered to users via cables, the new system — called BrainGate — replaces the cords with a small transmitter affixed atop a users' head. The unit then connects to an electrode array implanted in the brain's motor cortex. In a clinical trial, two participants with paralysis used the system to point, click, and type on a standard tablet computer. They both achieved similar typing speeds and point-and-click accuracy as those attained with wired systems. The researchers say it's the first time a device has transmitted the full spectrum of signals recorded by a sensor in the brain's motor cortex.

Read more of this story at Slashdot.

According to Reuters, Impossible Foods is preparing for a public listing which could value the U.S. plant-based burger maker at around $10 billion or more. From the report: This would be substantially more than the $4 billion the company was worth in a private funding round in 2020. It would highlight growing demand for plant-based meat products, driven by environmental and ethical concerns among consumers. Impossible Foods is exploring going public through an initial public offering (IPO) in the next 12 months or a merger with a so-called special purpose acquisition company (SPAC), the sources said. The Redwood City, California-based company has worked with a financial adviser to help manage discussions with SPACs after receiving offers at a lucrative valuation, the sources said. Going public through a SPAC could dilute existing Impossible Foods shareholders, however, by a greater extent than an IPO, the sources added. The sources, who requested because the discussions are private, cautioned that the deliberations are subject to market conditions and the company may opt to pursue another private fundraising round.

Read more of this story at Slashdot.

The NBA expects all arenas to be at full capacity next season, thanks to increased COVID-19 testing and more vaccines being administered. Another key aspect toward that effort is the NBA's new multiyear leaguewide partnership with Clear, a biometric screening company known for its expedited security process at hundreds of airports worldwide. ESPN reports: The partnership makes Clear's COVID-19 health screening technology available to all 30 teams in their NBA arenas, and it's expected to help facilitate more fans returning to games, though it's up to each team how to use the technology. Conversations for a leaguewide partnership began in early September. This is Clear's first leaguewide partnership with a professional sports league, but the company has been working with teams in MLS, MLB, NHL and the NFL. Clear first rolled out this program in a leaguewide format with the NHL's bubble season across two cities in Canada last year. As it pertains to attendance, fans can download the Clear app and upload an identifying document along with a selfie. To link their COVID-19 test results, fans log into their testing account through the app, and results will be linked to their health pass. Before entering the venue, fans can open the app, verify their identity with another selfie and then answer health survey questions. (There are also expected to be an unspecified number of Clear kiosks where fans receive a temperature check and scan their QR code.) Fans are issued a red or green notification depending on their COVID-related health information. A Clear spokesperson noted that the arenas only receive information about whether a fan has passed the requirements for access and not any private health information from the individual. They said that the Clear program is scalable, and could facilitate thousands of fans entering arenas.

Read more of this story at Slashdot.

"New vaccine trials hold great promise in the management of an East African strain of African swine fever, one of the most devastating diseases to afflict pigs," writes Cornell's Alliance for Science (a group who gives its mission as correcting misinformation and countering conspiracy theories slowing progress on issues including synthetic biology and agricultural innovations). Slashdot reader wooloohoo shares their report: Scientists at the International Livestock Research Institute (ILRI) are employing CRISPR Cas9 editing and synthetic biology to modify the ASFV genome in order to attenuate the virus for a live vaccine to help reduce deaths from African swine fever. Up to 10 vaccine candidates have been lined up for tests, in a project that commenced in 2016... African swine fever is present in 26 African countries, Steinaa observed, as well as in parts of Asia and Europe. An effective vaccine could be a breakthrough for pig farmers across the globe... With a 100 percent fatality rate and a highly contagious nature, African swine fever poses a potent threat to the global pig farming industry. The rapid spread of the disease portends social and economic disruptions wherever it strikes.

Read more of this story at Slashdot.

Slashdot reader wooloohoo shares a new article from Cornell's Alliance for Science, a group who gives its mission as correcting misinformation and countering conspiracy theories slowing progress on issues including synthetic biology and agricultural innovations: There are two types of chickens: the broilers that we eat and the layers that produce the eggs. The layers don't have enough meat to make them useful for human consumption and since only hens can lay eggs, that leaves the male layers useless. As a result, billions of newly hatched male layer chicks are killed each year. Now the Israeli ag-tech startup eggXYt has found a way to humanely address this dilemma through the use of CRISPR — the gene editing technique that allows scientists to make targeted, specific genetic tweaks... By using CRISPR, eggXYt's scientists can edit the genes of chickens to make them lay sex-detectable eggs... The global egg industry saves the costs and the ethical conundrum of killing half of its product and billions of additional eggs are added to the global market to help meet growing demand.

Read more of this story at Slashdot.

U.S. plant-based protein company Beyond Meat has signed global supply deals with fast food firms McDonald's and Yum! Brands, which includes KFC, Pizza Hut, Taco Bell and others. AgFunderNews reports: The three-year strategic agreement with McDonald's will see Beyond Meat become the 'preferred supplier' of patties for the fast food chain's new McPlant plant-based burger. Under their separate strategic partnership, Beyond Meat and Yum! Brands will co-develop a range of exclusive plant-based protein menu items for the latter's KFC, Pizza Hut, and Taco Bell chains. Bruce Friedrich, executive director of the Good Food Institute, said in comments sent to AFN that the two deals represent "the clearest sign yet that the future of meat will be plant-based." "The world's largest restaurant chains are placing plant-based meat directly on the plates of millions of customers around the world," he said. "With more restaurants and revenue than any other food chains on the planet, McDonald's and Yum! Brands will bring plant-based meat onto the mainstream menus of millions of people. When these restaurant chains move, the entire food industry takes notice."

Read more of this story at Slashdot.

A new research study at the University of Missouri is using CRISPR gene-editing technology to produce mosquitoes that are unable to replicate Zika virus and therefore cannot infect a human through biting. Slashdot reader wooloohoo shared an announcement from Cornell's Alliance for Science: Alexander Franz, an associate professor in the MU College of Veterinary Medicine, collaborated with researchers at Colorado State University... Their work was recently published in the journal Viruses. Franz added that the genetic modification is inheritable, so future generations of the altered mosquitoes would be resistant to Zika virus as well... "[W]e are simply trying to expand the toolbox and provide a solution by genetically modifying the mosquitoes to become Zika-resistant while keeping them alive at the same time." Franz' research is designed to help prevent another outbreak of Zika virus disease from occurring while also addressing concerns that have some have raised about reducing populations of mosquitoes, which are a food source for some animals... The study was funded by the National Institutes of Health.

Read more of this story at Slashdot.

An anonymous reader quotes a report from The Register: Failed blood-testing unicorn Theranos trashed vital incriminating evidence of its fraud, prosecutors said on Monday. The imploded startup's extensive testing data over three years, including its accuracy and failure rate, was "stored on a specially-developed SQL database called the Laboratory Information System (LIS)," according to a filing [PDF] in the fraud case against Theranos's one-time CEO Elizabeth Holmes and COO Sunny Balwani. The database "even flagged blood test results that might require immediate medical attention, and communicated this to the patient's physician," we're told. Theranos claimed to have perfected technology that would allow industry standard blood tests to be run at great speed and with just a drop of blood, revolutionizing the health industry, and causing the business to be valued at $10bn. The reality, however, was that for one set of tests, the failure rate was 51.3 per cent. What does that mean? Prosecutors explain: "In other words, Theranos's TT3 blood test results were so inaccurate, it was essentially a coin toss whether the patient was getting the right result. The data was devastating." So devastating that the database was subpoenaed by a grand jury digging into fraud claims against Holmes and Balwani. But when investigators turned to take a copy of the database, guess what? From the filing: "On or about August 31, 2018 -- three months after a federal grand jury issued a subpoena requesting a working copy of this database -- the LIS was destroyed. The government has never been provided with the complete records contained in the LIS, nor been given the tools, which were available within the database, to search for such critical evidence as all Theranos blood tests with validation errors. The data disappeared."

Read more of this story at Slashdot.

Reuters notes the "miraculous speed" of mRNA vaccines, while also calling it "a glimpse of what's possible if it can be applied post-pandemic to treat cancer or rare diseases." The vaccine market alone is worth about $35 billion each year, and investors apparently believe mRNA companies will capture around two-third of that, leading market researcher Bernstein to evalaute the combined worth of mRNA companies at nearly $180 billion. The technology is the closest thing yet to making medicine digital. MRNA vaccines essentially inject genetic code that instructs a recipients' cells to construct a part of the virus. The body recognizes the produced protein as foreign and mounts a future immune response when exposed. Moderna and BioNTech's vaccines show the technology works fast. Vaccines typically take a decade to develop. They took less than a year... The speed of mRNA therapeutics is a big advantage. For example, flu vaccines only reduce the risk of illness by up to 60% because makers must guess which strains will be prevalent each season. Sometimes they're wrong. Shaving months off means better guesses, and higher efficacy. The bigger opportunity comes from the validation of the mRNA "platform". Instructing cells to produce desired proteins could lead to multiple advances. Perhaps they can instruct the body to more vigorously attack cancerous cells or repair damaged tissue. Producing missing proteins might fight inherited diseases... Success against Covid-19 means these companies will be flush with cash from sales and attract partnerships and scientific talent. That should make 2021 a watershed.

Read more of this story at Slashdot.

An anonymous reader quotes a report from CNN: A biotech conference in Boston last February that's already been flagged as a Covid-19 superspreading event led to at least 245,000 other cases across the US and Europe, a new genetic fingerprinting study shows. One single case seems to have been responsible for many of the other eventual cases, the team at the Broad Institute in Massachusetts reported. Their study finds two particular genetic fingerprints of viruses associated with the conference and then tracks those lineages across the US. One "was exported from Boston to at least 18 US states as well as to other countries, including Australia, Sweden, and Slovakia," the team, led by Bronwyn MacInnis, director of pathogen genomic surveillance at the Broad Institute, wrote in the journal Science. One was especially bad. A virus carrying one mutation -- a small genetic change they've flagged as C2416T -- was apparently carried to the conference by a single person, and ended up infecting 245,000 people. A subset of the viral strain with a mutation known as G26233T ended up in 88,000 of these cases. "A single introduction had an outsize effect on subsequent transmission because it was amplified by superspreading in a highly mobile population very early in the outbreak, before many public health precautions were put in place," the team wrote. "While Massachusetts accounted for most early spread related to the conference, Florida accounted for the greatest proportion of cases overall," they added.

Read more of this story at Slashdot.

Long-time Slashdot reader sixoh1 shares "an interesting spin on biotechnology tools that we've been seeing explode lately like Crisper-CAS and mRNA." Ars Technica writes: This is in no way a route to a practical therapy, but it does provide a fantastic window into what we can accomplish by manipulating biology. The whole effort described in the new paper is focused on a simple idea: if you figure out how to wreck one of the virus's key proteins, it won't be able to infect anything. And, conveniently, our cells have a system for destroying proteins, since that's often a useful thing to do... This system relies on a small protein called "ubiquitin." When a protein is to be targeted for destruction, enzymes called ubiquitin ligases chemically link a chain of ubiquitins to it. These serve as a tag that is recognized by enzymes that digest any proteins with ubiquitin attached to them. So, the idea behind the new work is to identify a key viral protein and figure out how to attach ubiquitin to it... Unfortunately, there are no proteins that attach ubiquitin to the viral spike protein. Or, rather, there were no proteins that fit that description. But a team at Harvard has now produced one. They fed atomic-level details of the proteins' structure into software that finds the most energetically-favored interactions between proteins, simulated mutations, and eventually engineered the most promising ones to test their efficacy, ultimately cutting the presence of the viral spike protein in tested cells by 60 percent. Ars Technica ultimately calls it "A mildly insane idea for disabling the coronavirus," though "Unfortunately, it's also likely to be absolutely useless... this is likely to be a non-starter, especially given that there are promising vaccines and many other potential therapies ahead of it in the pipeline for safety testing." Yet "while the details of this work aren't really significant, the fact that we've developed all the underlying technology needed for it is worth keeping in mind."

Read more of this story at Slashdot.

An anonymous reader quotes a report from The Guardian: PhD in genetics might seem like an unusual requirement for the role of head chef. It makes more sense when the man running the kitchen is not just in charge of frying your chicken burger -- he created the meat himself. "This burger takes something between two to three days to grow," says Tomer Halevy as he chops red onions, iceberg lettuce and avocado. He proceeds to batter what appears to be a strip of raw chicken before dipping it in breadcrumbs. Halevy uses the word "grow" because chickens do not need to be slaughtered en masse to produce this type of meat. Cells taken from "source" chickens are cultured in a laboratory, creating potentially endless supplies of muscle and fat tissue. Some cells were removed from eggs, meaning the meat is from birds that were never even born. The result is the signature dish of a new venture in Israel, the Chicken, the world's first cultured meat restaurant experience. Still closed to the public owing to coronavirus restrictions, the eatery near Tel Aviv opened its doors to the Guardian for the first private visit by a journalist. At the Chicken, bottles of red wine line the walls, black stools surround circular tables, and the warm glow of hanging bulbs lights the restaurant. The entire back wall is made of glass. Behind it is the production facility where lab-coated scientists wander around between large metal vats. It is petri-dish-to-table service. "The meat was made on the other side of the glass. That's true local production of meat," jokes Ido Savir, CEO of the restaurant's parent company, SuperMeat. The breaded patty is deep-fried in oil, before being placed on a sweet brioche bun, flavored by wasabi and chilli mayonnaise, with a side of sweet potato chips. Similar to many chicken burgers, it breaks and flakes when pulled apart and is extremely tender. It tastes, at least to this reporter, like a chicken burger. Halevy, who also holds the role of head of product at SuperMeat, explains that muscle cells naturally contract when they are grown, making the fibers that result in the flakes of the burger that you would expect. While Halevy says he could make a recreation of a chicken breast -- with longer fibers and a dryer, denser bite -- one was not offered, and others in the industry have said a fillet is much harder to create outside the bird. For now, like others in the nascent industry, the start-up is focused on minced chicken. It is aiming to sell to meat companies that often reprocess chicken anyway, for example, into patties and nuggets. The report notes that SuperMeat cannot charge customers since there is no regulation around cultured meat in Israel. Those who try the product must also sign a waiver agreeing to "voluntarily assume any and all risks." The industry is still very much in its infancy, but it was given a significant boost this week when Singapore became the first state to approve the sale of cultured meat.

Read more of this story at Slashdot.

Singapore has granted San Francisco start-up Eat Just Inc. regulatory approval to sell its laboratory-grown chicken in the city-state -- the world's first government to allow the sale of cultured meat. CNN reports: The product, created from cultured chicken cells, has been approved as an ingredient in chicken bites following Singapore Food Agency (SFA) approval, Eat Just said Tuesday. Initially, the chicken bites will debut in a Singapore restaurant, with plans for wider expansion into dining and retail establishments in the country, Josh Tetrick, co-founder and CEO of Eat Just told CNN Business. The product will be priced at parity with premium chicken, he added. The cultured meat is created in a bioreactor -- an apparatus in which a biological reaction or change takes place -- Eat Just said. It has a high protein content and is a rich source of minerals, according to the company, which plans to sell the product under the GOOD Meat brand. For now, with manufacturing hubs in Singapore and Northern California, the company only has approval to sell the meat in Singapore, but it hopes to expand sales of cultured meat -- including cultured beef -- into the US and Western Europe, Tetrick said.

Read more of this story at Slashdot.

schwit1 shares a report from Phys.Org: Forget glue, screws, heat or other traditional bonding methods. A Cornell University-led collaboration has developed a 3-D printing technique that creates cellular metallic materials by smashing together powder particles at supersonic speed. This form of technology, known as "cold spray," results in mechanically robust, porous structures that are 40% stronger than similar materials made with conventional manufacturing processes. The structures' small size and porosity make them particularly well-suited for building biomedical components, like replacement joints. The team's paper, "Solid-State Additive Manufacturing of Porous Ti-6Al-4V by Supersonic Impact," published Nov. 9 in Applied Materials Today. "If we make implants with these kind of porous structures, and we insert them in the body, the bone can grow inside these pores and make a biological fixation," Moridi said. "This helps reduce the likelihood of the implant loosening. And this is a big deal. There are lots of revision surgeries that patients have to go through to remove the implant just because it's loose and it causes a lot of pain." Moridi added: "We only focused on titanium alloys and biomedical applications, but the applicability of this process could be beyond that. Essentially, any metallic material that can endure plastic deformation could benefit from this process. And it opens up a lot of opportunities for larger-scale industrial applications, like construction, transportation and energy."

Read more of this story at Slashdot.